Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males

Managing body composition in hypogonadal males typically relies on androgen replacement therapy, but this approach may not fully address all aspects of metabolic health. This study by Sinha, Balasubramanian, Tatem, and colleagues explored the role of growth hormone secretagogues like sermorelin as complementary tools for body composition optimization.

The researchers reviewed evidence on growth hormone secretagogues in the context of hypogonadal male health, examining how these peptides can enhance body composition outcomes when used alongside or beyond traditional androgen therapy. The review addressed both the physiological rationale and clinical evidence for this approach.

The findings demonstrated that growth hormone secretagogues like sermorelin play a valuable role in optimizing body composition in hypogonadal males. These peptides help improve lean muscle mass, reduce body fat, and enhance overall metabolic function in ways that complement but go beyond what androgen therapy alone can achieve.

For male patients dealing with hypogonadism and its effects on body composition, this research supports a more comprehensive treatment approach. Incorporating sermorelin into treatment protocols alongside hormone optimization may help patients achieve better overall body composition and metabolic health outcomes.